Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24618836 | 1.00 | TRPA1 (0.32) | TRPA1ESR2 | |
| SCHEMBL6757997 | 1.00 | TRPA1 (0.32) | TRPA1ESR2 | |
| SCHEMBL6757987 | 1.00 | TRPA1 (0.32) | TRPA1ESR2 | |
| SCHEMBL6758030 | 1.00 | TRPA1 (0.32) | TRPA1ESR2 | |
| SCHEMBL6757572 | 1.00 | TRPA1 (0.32) | TRPA1ESR2 | |
| SCHEMBL7909541 | 0.86 | TRPA1 (0.42) | TRPA1 | |
| SCHEMBL21961600 | 0.86 | TRPA1 (0.42) | TRPA1 | |
| SCHEMBL21961177 | 0.86 | TRPA1 (0.42) | TRPA1 | |
| SCHEMBL3433997 | 0.85 | ESR2 (0.38) | ESR2 | |
| SCHEMBL6759411 | 0.85 | ESR2 (0.38) | ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020081508-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| US-9302120-B2 | Spiro-oxindole MDM2 antagonists | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-04-05 | — | — | US | disclosed |
| US-20140148494-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-05-29 | — | — | US | disclosed |
| US-8680132-B2 | Spiro-oxindole MDM2 antagonists | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120122947-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148494-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | TP53, MDM2, TP53BP1 | TRPA1 2963/4885ESR2 258/4885 |
| US-20120122947-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | TP53, MDM2, TP53BP1 | TRPA1 2963/4885ESR2 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.